Abstract #1281

Value of Contrast-Enhanced MRA of the Peripheral Arteries at 3T: Results of a Large European Multicenter Trial Comparing Gadoterate Meglumine-MRA to Gadobutrol-MRA with DSA

Michael Lell¹, Javier Arnaiz², Denis Krause³, Luis Marti-Bonmati⁴, Manuela Aschauer⁵, Armando Tartaro⁶, Massimo Lombardi⁷, Marta Burrel⁸, Reynald Izzillo⁹, Christian Loewe¹⁰

¹Radiology Department, University-Hospital, Erlangen, Germany; ²University Hospital Marqus de Valdecilla, Santander, Spain; ³Dpartement de Radiologie et d'Imagerie Mdicale Diagnostique et Thrapeutique, CHU Le Bocage, Dijon, France, Metropolitan; ⁴Dr Peset Hospital, Valencia, Spain; ⁵Radiology, Universittsklinikum fr Radiologie, Graz, Austria; ⁶University Gabriel d'Annuzio of Chieti-Pescara, Chieti, Italy; ⁷Clinical Physiology Institute CNR National Research Council, Pisa, Italy; ⁸Hospital Clinico, Barcelona, Spain; ⁹Radiology, Centre Cardiologique du Nord, Saint Denis, France; ¹⁰Radiology, AKH Wien - Medizinische Universitt Wien, Vienna, Austria

To date, no prospective randomized trial comparing peripheral CE-MRA at 3T to the reference standard DSA has been performed so far including a large patient population. This multicentre trial including 189 patients was primarily aimed to compare the degrees of agreement in stenosis detection between contrast enhanced-MRA and DSA using two different contrast agents (gadoterate meglumine (Dotarem) or gadobutrol (Gadovist)) inpatients with peripheral arterial occlusive disease (PAOD). This study demonstrates the value of peripheral MRA at 3T for diagnosis and treatment planning in patients suffering from PAOD without any difference between gadoterate meglumine-MRA and gadobutrol-MRA.